Hospira's filgrastim biosimilar given CHMP nod
This article was originally published in Scrip
Executive Summary
The EU's CHMP has adopted a positive opinion on Hospira's Nivestim (filgrastim; 12MU/0.2ml, 30MU/0.5mg, 48MU/0.5ml) solution for injection or infusion for the treatment of neutropenia. Nivestim is a biosimilar of Amgen's Neupogen which was the reference product for the application.